PP.13.24

Abstract

Objective: Jupiter Study supports the clinical use of the inflammatory status to limit cardiovascular events.Inflammation is now a theoretic concept which will start to be applied in practice to evaluate CV risk and the therapeutic target. The aim of this study is to investigate the relation between the classical cardiovascular risk factors and inflammation markers (hsCRP, TNF-alpha, MPO-mieloperoxidase, AOPP-advance oxidation protein products) in an adult patients group with metabolic syndrome (MetS). Design and method: MPO and AOPP were assessed spectrophotommetrically, hs-CRP and TNF-alpha by sandwich ELISA, and all the other risk factors (BMI, fasting glucose, lipid profile) by validated standard procedures, respectively, in a group of 108 patients diagnosed with the metabolic syndrome, free of coronary desease or cardiac insufficiency and without having any treatment vs. 33 age-, and sex-matched control group patients (C). Results: The CV SCORE risk for MetS group was moderate. The MPO level was not statistical significantly different between the two groups.The AOPP level and the other inflammatory markers consideredwas were higher in MetS group. TNF-alpha was strongly correlated with the number of inclusion criteria in MetS, was average correlated with weight, waist, BMI, FPG, serum TG, HDL-c and is not correlated with the values of blood pressure, uric acid, LDL-c, TC. HsCRP are significantly higher than the control group and are strongly correlated with the number of criteria for MetS, waist, FPG, HbA1c, LDL-C and has an average correlation with SBP, BMI. Conclusions: The MPO level was not statistical significantly different between the two groups, probably because of one of the inclusion criteria, the absence of the coronary disease, which translate into the absence of an important atherosclerotic plaque, which can potentially break down. Moreover for the MetS group we found higher values not only for the AOPP level, but also for all the other inflammatory markers considered, probably due to the inclusion of patients with DM type II or with modified glucose tolerance who already have an endothelial dysfunction, even though most of the patients were non-smokers and were not diagnosed with end organ damage.